Familial Insomnia Prion Disease: Understanding the Fatal Genetic Sleep Disorder

Introduction to Familial Insomnia Prion Disease

Fatal Familial Insomnia (FFI) is an exceptionally rare and devastating inherited neurodegenerative condition, falling under the umbrella of prion diseases. This progressive disorder is characterized primarily by intractable insomnia, which is not merely sleeplessness, but a profound disruption of the sleep-wake cycle, alongside a cascade of other debilitating symptoms. At its core, Familial Insomnia Prion disease is genetically determined, stemming from a specific mutation in the prion protein gene (PRNP). This genetic anomaly leads to the misfolding of prion proteins, which accumulate in the thalamus, a critical brain region responsible for sleep regulation, among other vital functions.

The progression of familial insomnia prion is marked by escalating insomnia, followed by a range of autonomic malfunctions such as rapid heartbeat (tachycardia), excessive sweating (hyperhidrosis), and elevated blood pressure (hypertension). Cognitive decline also ensues, manifesting as deficits in short-term memory and attention. Patients may experience balance issues, movement problems, and endocrine system irregularities. Currently, there is no cure for familial insomnia prion disease, and the condition invariably leads to death, typically within an average span of 18 months from onset.

Diagnosing familial insomnia prion relies heavily on clinical evaluation. A thorough patient history and a comprehensive neurological examination are essential. While there are no disease-modifying treatments, management focuses on alleviating symptoms and providing palliative care to enhance patient comfort and quality of life during the disease course. This article aims to provide a detailed overview of familial insomnia prion, enhancing understanding for healthcare professionals and caregivers.

Genetic Basis and Etiology of Familial Insomnia Prion

Familial insomnia prion disease is rooted in the genetic domain, specifically within the PRNP gene. This gene provides the blueprint for creating prion protein (PrPC), a normal protein found in various body tissues, particularly in the brain. In individuals with familial insomnia prion, a mutation occurs at codon 178 of the PRNP gene. This specific mutation, known as D178N, involves a substitution of aspartic acid (D) with asparagine (N) at position 178 of the protein sequence. This mutation is autosomal dominant, meaning that only one copy of the mutated gene from one parent is sufficient to inherit the disease.

This genetic defect causes the prion protein to misfold into an abnormal form, often denoted as PrPSc. Unlike normal PrPC, PrPSc is resistant to degradation and tends to aggregate, forming clumps within the brain, particularly in the thalamus. This accumulation disrupts normal neuronal function and triggers a cascade of neurodegenerative processes. Familial insomnia prion is categorized within a spectrum of inherited prion diseases, which also includes conditions like Gerstmann-Sträussler-Scheinker syndrome and familial Creutzfeldt-Jakob disease. These diseases share a common pathogenic mechanism involving prion protein misfolding but differ in their specific genetic mutations, clinical presentations, and affected brain regions.

The M129 genotype on the same PRNP gene further influences the expression of familial insomnia prion. The D178N mutation in conjunction with the methionine (M) allele at codon 129 is strongly associated with the FFI phenotype. While the exact trigger for prion protein misfolding remains an area of ongoing research, it’s understood that a critical mass of misfolded prion protein accumulation is necessary to initiate the disease process.

Epidemiology and Global Occurrence of Familial Insomnia Prion

While considered exceedingly rare, familial insomnia prion disease has been documented globally. Hundreds of cases have been reported, with a notable prevalence in Europe and Asia. Recent data indicates a potential rise in reported cases, particularly in regions like China, which may reflect increased awareness and diagnostic capabilities.

Epidemiological studies provide insights into the demographics of familial insomnia prion. Analyses of reported cases indicate a slightly higher prevalence among men compared to women. The typical age of disease onset is around 47 to 50 years, with a broad range spanning from the late teens to the mid-70s. The duration of the illness, from symptom onset to death, averages approximately 13 months, although this can vary significantly, ranging from a few months to up to four years.

Geographical and genetic variations can influence the clinical presentation of familial insomnia prion. For instance, studies suggest that individuals of Asian descent may exhibit a higher incidence of motor symptoms, sleep-related breathing difficulties, and laryngeal stridor compared to other populations. Conversely, symptoms like double vision (diplopia) and muscle twitching (myoclonus) might be less common in Asian cases. These regional variations underscore the complex interplay between genetic background and disease phenotype in familial insomnia prion. Overall, genetic prion diseases remain exceptionally rare, with an annual incidence of about 1 to 1.5 new cases per million people, and hereditary forms accounting for approximately 10% of all prion disease cases.

Pathophysiology and Neuropathological Changes in Familial Insomnia Prion

The core pathology of familial insomnia prion disease is centered in the thalamus, a deep brain structure vital for relaying sensory and motor signals and regulating consciousness and sleep. Neuropathological examinations reveal significant neuronal loss and gliosis (scarring of brain tissue due to glial cell proliferation) predominantly within specific thalamic nuclei. These thalamic lesions are considered the primary drivers of the severe sleep disturbances and autonomic dysfunctions characteristic of FFI.

However, the neurodegeneration in familial insomnia prion is not confined to the thalamus. Studies have demonstrated that other brain regions, including the parietal, temporal, and frontal lobes of the cerebral cortex, are also affected, albeit to varying degrees. The occipital lobe, responsible for vision, tends to be less involved. The extent of cortical involvement, particularly the degree of spongiosis (vacuole formation in neurons) and astrogliosis, appears to correlate with the duration of the disease.

Interestingly, the pattern of prion protein deposition differs from the extent of neuronal damage. Prion protein aggregates are found early in the disease course in the brainstem and thalamus, with the thalamus exhibiting the most pronounced degenerative changes. The precise reasons for this selective vulnerability of the thalamus in familial insomnia prion are not fully elucidated. This pattern of neurodegeneration explains the multifaceted clinical presentation of the disease, encompassing sleep disruption, autonomic instability, and cognitive and motor impairments.

Histopathological Findings in Familial Insomnia Prion

Histopathological analysis of brain tissue from individuals with familial insomnia prion reveals distinctive features that aid in understanding the disease’s impact on brain structure at a microscopic level. Immunohistochemical studies, using techniques like Western blotting, demonstrate a complex relationship between prion protein deposition and the severity of tissue damage. Notably, the amount and location of abnormal prion protein deposits do not always directly correspond to the degree of histopathological changes, suggesting that the neurotoxic mechanisms are multifaceted.

In the cerebellum, a brain region crucial for motor coordination, prion protein deposits in familial insomnia prion exhibit a unique pattern. They are concentrated in the molecular layer and present as patchy, strip-like arrangements oriented perpendicularly to the cerebellar surface. This specific cerebellar pathology contributes to the motor coordination problems seen in some FFI patients.

Further detailed examination at the cellular level has revealed striking findings. In some cases, individual neurons within the inferior olivary nuclei of the brainstem contain substantial protease-resistant prion protein deposits within vacuoles. These vacuolar changes are reminiscent of those observed in brainstem neurons in bovine spongiform encephalopathy (BSE), commonly known as “mad cow disease,” another prion disease. These histopathological characteristics provide valuable insights into the cellular and molecular events underlying neurodegeneration in familial insomnia prion.

Clinical Presentation: History and Physical Examination in Familial Insomnia Prion

Familial insomnia prion typically manifests clinically in midlife, with symptom onset most commonly occurring between the ages of 20 and 61, averaging around 50 years old. The clinical presentation of familial insomnia prion can be heterogeneous, meaning symptoms can vary among individuals, even within the same family. However, a detailed history and neurological examination are critical, as the diagnosis remains primarily clinical.

When evaluating a patient for possible familial insomnia prion, clinicians focus on a constellation of core symptoms that have been formalized into diagnostic criteria. These core features, which usually persist for a duration, include:

Organic Sleep Disturbances: This is the hallmark of familial insomnia prion, characterized by intractable insomnia that resists conventional treatments. It can manifest as agrypnia excitata (a state of near-total sleeplessness with motor and autonomic hyperactivity), often accompanied by laryngeal stridor (noisy breathing). Other sleep disturbances include sleep apnea, restless sleep with frequent position changes, and hypnic jerks (sudden muscle twitches upon falling asleep).
Neurologic and Mental Health Impairment: Cognitive decline is a prominent feature, typically presenting as rapidly progressive dementia. Other neurological signs can include ataxia (loss of coordination), myoclonus, hallucinations, delusions, and personality changes such as depression, anxiety, apathy, and confusion.
Progressive Autonomic and Systemic Abnormalities: Dysfunction of the autonomic nervous system is characteristic, leading to symptoms like hypertension, tachycardia, irregular breathing patterns, hyperthermia (elevated body temperature), excessive sweating, and significant weight loss (often exceeding 10% of body weight within six months).

Supportive clinical features that further strengthen the suspicion of familial insomnia prion include:

Family History: A documented family history of organic insomnia symptoms is a significant risk factor and supportive criterion.
Probable Organic Insomnia: Evidence of disrupted sleep patterns from polysomnography (PSG) or sleep diaries, such as loss of circadian rhythm, fragmented sleep, reduced total sleep time, and sleep-wake cycle reversal, further supports the diagnosis. Involuntary movements during sleep, observed on video PSG, are also supportive findings.

Diagnostic Evaluation of Familial Insomnia Prion

Diagnosing familial insomnia prion is primarily a clinical process, relying heavily on the patient’s symptom presentation and medical history. However, various diagnostic studies play a crucial role in supporting the clinical diagnosis and, importantly, in excluding other conditions that may mimic FFI symptoms.

Diagnostic Studies:

Initial Blood Work: Routine blood tests, including a complete blood count (CBC), erythrocyte sedimentation rate (ESR), serum chemistry, liver function tests (LFTs), ammonia levels, and blood cultures, are performed to rule out other potential causes of the patient’s symptoms, such as infections or metabolic disorders.
Evaluation for Reversible Cognitive Decline: Tests to identify reversible causes of cognitive impairment are essential. These include thyroid function tests (TFTs), vitamin B-12 and folate levels, and serological tests for neurosyphilis and HIV.
Polysomnography (PSG): PSG, or sleep study, is a key diagnostic tool in familial insomnia prion. It typically reveals a significant reduction in total sleep time and disruptions in the transitions between different sleep stages. Characteristic PSG findings include reduced REM sleep, decreased sleep efficiency, and diminished slow-wave sleep.
Electroencephalogram (EEG): While EEG is a standard test for neurological disorders, its utility in familial insomnia prion is somewhat limited. Periodic sharp-wave complexes (PSWC) on EEG are suggestive of prion disease in general but are not commonly seen in genetic forms like FFI. Patients with familial insomnia prion usually show generalized slowing on EEG, which is non-specific, and typically lack the characteristic PSWC seen in sporadic CJD.
Cerebrospinal Fluid (CSF) Analysis: CSF biomarkers, such as the 14-3-3 protein, are not specific for familial insomnia prion. While these biomarkers can indicate neuronal death, they are elevated in various neurological conditions and thus have limited diagnostic specificity for FFI.

Imaging Studies:

Computed Tomography (CT) and Magnetic Resonance Imaging (MRI): Conventional CT and MRI scans of the brain are often normal in the early stages of familial insomnia prion. Their main role is to exclude other neurological conditions, such as tumors, strokes, or hydrocephalus. However, as familial insomnia prion progresses, MRI may reveal reduced thalamic diffusion, indicating gliosis in this region. Atrophic changes in the thalamus and other brain areas may also become apparent in later stages.
Fluorodeoxyglucose Positron Emission Tomography (FDG-PET): FDG-PET scans can be more informative in familial insomnia prion diagnosis. They often demonstrate hypometabolism (reduced glucose utilization, indicating neuronal dysfunction) in the thalamus and cingulate cortex, while typically sparing the occipital lobe. This pattern of hypometabolism can support the diagnosis of FFI.

Molecular Genetic Testing: Genetic testing is crucial for confirming the diagnosis of familial insomnia prion. Targeted analysis for the D178N mutation in the PRNP gene or full gene sequencing is recommended for suspected cases. Positive genetic testing provides definitive confirmation of familial insomnia prion.

Histopathological Testing: Brain biopsy is generally not required for diagnosing familial insomnia prion and is not diagnostically specific. However, in atypical cases or when other diagnoses are strongly considered, brain biopsy may be performed to rule out treatable neurological diseases.

Diagnostic Approach and Criteria:

The diagnostic approach to familial insomnia prion integrates clinical features, supportive investigations, and genetic testing. The 2022 international diagnostic criteria provide a structured framework for assessing the likelihood of FFI. These criteria incorporate core clinical features, supportive findings, and exclusionary factors.

Exclusionary Features: Features that make familial insomnia prion less likely include periodic sharp wave complexes on EEG, hyperintense signals in the caudate nucleus and putamen or in multiple cortical regions on MRI, and clinical deficits that are better explained by alternative diagnoses.
Diagnostic Studies: Positive molecular genetic testing for a pathogenic PRNP mutation, specifically D178N, is a definitive diagnostic criterion.
Probability of FFI Diagnosis: Based on these criteria, the probability of familial insomnia prion is categorized as:
- Possible FFI: Two out of three core clinical features present, without any exclusionary features.
- Probable FFI: Two out of three core clinical features, plus at least one supportive feature, and no exclusionary features.
- Definite FFI: Two out of three core clinical features, along with positive diagnostic genetic testing.

This structured approach allows for a more standardized and reliable diagnosis of familial insomnia prion, especially in the early stages when symptoms may be subtle or overlap with other conditions.

Treatment and Management Strategies for Familial Insomnia Prion

Currently, there is no cure for familial insomnia prion disease. Treatment strategies are primarily focused on symptomatic relief and palliative care. The goal of management is to alleviate the distressing symptoms of FFI and improve the patient’s quality of life as much as possible.

Symptomatic Management:

Medication Review: A critical first step is to review and discontinue any medications that might exacerbate confusion, memory problems, or insomnia. Certain drugs can worsen cognitive impairment or disrupt sleep patterns, and identifying and stopping these can be beneficial.
Sedatives and Hypnotics: Paradoxically, individuals with familial insomnia prion often show a poor response to traditional sedatives and hypnotics, including benzodiazepines and barbiturates. These medications may have limited efficacy in inducing sleep and can sometimes worsen confusion or other symptoms.
Gamma-Hydroxybutyrate (GHB): In some case reports, GHB has shown promise in inducing slow-wave sleep (SWS) in patients with familial insomnia prion. However, its use is not widespread, and further research is needed to establish its efficacy and safety in FFI.
Nutritional Support: Swallowing difficulties can develop as familial insomnia prion progresses. In such cases, placement of a feeding tube may be necessary to ensure adequate nutrition and hydration.

Experimental and Investigational Therapies:

Several therapeutic approaches have been investigated for prion diseases, including familial insomnia prion, but with largely inconclusive results to date. These include:

Pentosane Polysulfate: This compound has been studied for its potential to inhibit prion replication, but clinical trials have not demonstrated significant benefit in prion diseases.
Quinacrine and Amphotericin B: These drugs have also been explored for their anti-prion activity, but clinical studies have failed to show clear efficacy in treating prion diseases.
Doxycycline: A clinical trial is ongoing in Italy, investigating the use of doxycycline, an antibiotic, to potentially prevent or delay the onset of prion disease in individuals who are carriers of the PRNP D178N/M129 mutation. This preventive study is administering doxycycline to mutation carriers and comparing outcomes to non-carrier controls. Results from this trial are eagerly awaited.
Immunotherapy: Immunotherapy approaches, including antibody vaccines, dendritic cell vaccines, and adoptive transfer of prion protein-specific T-lymphocytes, are under preclinical and early clinical investigation. The aim of immunotherapy is to target and clear the misfolded prion protein (PrPSc). Antibody vaccines are designed to recognize unique epitopes present only on the misfolded prion protein. While showing promise in vitro and in animal models, immunotherapy for human prion diseases is still in the early stages of development.

Palliative and Psychosocial Care:

Given the lack of curative treatments, palliative care is a cornerstone of familial insomnia prion management. This includes:

Pain and Symptom Management: Addressing pain, discomfort, and other distressing symptoms with appropriate medications and supportive measures.
Psychosocial Support: Providing comprehensive psychosocial support for both the patient and their family is crucial. Familial insomnia prion is a devastating illness, and emotional, psychological, and practical support are essential.
Hospice Care: Early involvement of hospice care is highly beneficial. Hospice provides specialized end-of-life care, focusing on maximizing comfort, dignity, and quality of life for the patient and offering support to the family.

Differential Diagnosis of Familial Insomnia Prion

When evaluating a patient with suspected familial insomnia prion, it is essential to consider other conditions that can present with overlapping symptoms. Prion diseases, in general, share some clinical features, and differentiating them is crucial. Conditions to consider in the differential diagnosis include:

Sporadic Creutzfeldt-Jakob Disease (sCJD) and Familial Creutzfeldt-Jakob Disease (fCJD): These are other forms of prion disease. sCJD is more common and typically progresses more rapidly than familial insomnia prion, with a later age of onset. Both sCJD and fCJD often present with prominent memory problems, confusion, myoclonus, and ataxia. Histopathologically, sCJD is characterized by more widespread spongiform degeneration and astrogliosis compared to familial insomnia prion.
Sporadic Fatal Insomnia (sFI): This is a very rare condition that clinically and pathologically mimics familial insomnia prion but occurs without a PRNP gene mutation. sFI is even less understood than FFI, and research into its pathogenesis is ongoing.
Gerstmann-Sträussler-Scheinker Syndrome (GSS): Another genetic prion disease, GSS typically presents with cerebellar dysfunction as a primary feature, leading to ataxia and coordination problems. Sleep disturbances are less prominent in GSS, and cognitive decline, if present, is usually milder and occurs later in the disease course. GSS also has a different genetic basis, involving various mutations in the PRNP gene distinct from the D178N mutation of familial insomnia prion.
Variably Protease-Sensitive Prionopathy (VPSPr): This is a recently recognized prion disease that can present with variable symptoms, including aphasia and behavioral changes. Diagnosis often requires histopathological examination.

Beyond other prion diseases, non-prion conditions must also be considered:

Lithium Toxicity: Lithium overdose can cause neurological symptoms, including confusion and cognitive impairment.
Familial Myoclonic Dementia: This is a group of genetic disorders characterized by myoclonus and dementia.
Diffuse Lewy Body Disease (DLBD): DLBD is a neurodegenerative dementia that can present with cognitive fluctuations, visual hallucinations, and parkinsonism.
Chronic Meningitis: Chronic infections of the brain and meninges can cause progressive neurological symptoms.
Dementia as a Paraneoplastic Syndrome: Certain cancers can trigger neurological syndromes, including dementia.
Dementia in Motor Neuron Disease: Some forms of motor neuron disease can be associated with cognitive impairment.
Non-Herpes Viral Encephalitis: Viral infections of the brain can cause acute or subacute neurological syndromes.
Hashimoto Encephalopathy (SREAT): Steroid-responsive encephalopathy associated with autoimmune thyroiditis is a rare autoimmune condition that can cause encephalopathy and cognitive dysfunction.
Limbic Encephalitis and Other Paraneoplastic Syndromes: Autoimmune or paraneoplastic limbic encephalitis can present with psychiatric and cognitive symptoms.

Furthermore, reversible causes of dementia, such as hydrocephalus, HIV encephalopathy, and other infections, must be ruled out. Neurodegenerative diseases such as Alzheimer’s disease, frontotemporal dementia, corticobasal degeneration, and multiple system atrophy, although typically slower in progression, should also be considered in the differential diagnosis, particularly in the early stages of familial insomnia prion.

Disease Staging in Familial Insomnia Prion

Familial insomnia prion disease progression can be described in four clinical stages, although there can be overlap and variability in individual cases:

Stage 1: This initial stage is characterized by the subacute onset of insomnia that gradually worsens over a few months. Psychiatric symptoms, such as phobias, paranoia, and panic attacks, may emerge during this phase. Patients may also experience vivid or lucid dreaming.
Stage 2: Over the next approximately five months, psychiatric symptoms intensify, insomnia worsens, and hallucinations may develop. Autonomic dysfunction becomes more prominent, manifesting as sympathetic hyperactivity (e.g., increased heart rate, blood pressure, sweating).
Stage 3: This is a relatively short stage, lasting around three months. It is marked by near-total insomnia and severe disruption of the sleep-wake cycle.
Stage 4: The final stage can extend for six months or longer. It is characterized by rapid cognitive decline progressing to dementia. Patients lose the ability to move and speak voluntarily, eventually leading to coma and death.

Prognosis and Disease Course of Familial Insomnia Prion

Familial insomnia prion disease carries a universally fatal prognosis. The disease course typically ranges from 7 to 36 months, with an average duration of approximately 18 months from symptom onset to death. Genetic factors can influence disease duration. Individuals who are homozygous for methionine at codon 129 of the PRNP gene (Met-Met) tend to have a shorter mean survival time compared to heterozygotes (Met-Val).

Complications Associated with Familial Insomnia Prion

Familial insomnia prion leads to a wide range of complications due to its progressive neurodegenerative nature and systemic effects. These complications span autonomic, cognitive, motor, and endocrine systems. As detailed in the “History and Physical” section, these include:

Severe and intractable insomnia
Autonomic instability (tachycardia, hypertension, hyperthermia, hyperhidrosis, breathing irregularities)
Cognitive decline and dementia
Motor dysfunction (ataxia, balance problems, speech difficulties)
Endocrine abnormalities
Psychiatric symptoms (anxiety, depression, hallucinations, delusions)
Weight loss and nutritional decline
Increased susceptibility to infections (in later stages)

These complications contribute to the significant morbidity and mortality associated with familial insomnia prion.

Deterrence and Patient Education for Familial Insomnia Prion

Given the genetic nature of familial insomnia prion, deterrence in the traditional sense is not applicable. However, patient and family education is paramount. Essential aspects of education include:

Disease Course and Prognosis: Providing clear and compassionate information about the fatal nature of familial insomnia prion and its typical disease progression.
Limited Treatment Options: Honest communication about the current lack of curative treatments and the focus on symptomatic and palliative care. However, also inform about ongoing research efforts and potential future therapies.
Genetic Counseling: Offering genetic counseling to family members is critical. This allows at-risk individuals to understand their inheritance risk, consider genetic testing options, and make informed decisions about family planning and future healthcare.
Support Resources: Connecting families with support groups, patient advocacy organizations, and resources for coping with prion diseases and neurodegenerative conditions.

Enhancing Healthcare Team Outcomes in Familial Insomnia Prion Management

Managing familial insomnia prion effectively requires a collaborative, interprofessional healthcare team. Optimal care involves the expertise of various specialists:

Sleep Specialists: For managing the complex sleep disturbances.
Neurologists: For diagnosis, neurological symptom management, and overall disease management.
Psychiatrists and Psychologists: To address the psychiatric and psychological aspects of the disease for both the patient and family.
Genetic Counselors: To provide genetic risk assessment and counseling to families.
Palliative Care Nurses and Physicians: To deliver specialized palliative care and symptom management.
Hospice Care Teams: To provide comprehensive end-of-life care and support.
Social Workers: To assist with practical, social, and logistical challenges faced by patients and families.

Effective communication and coordination among team members are essential. An interprofessional approach ensures holistic care, addressing the medical, psychological, social, and emotional needs of patients and families facing familial insomnia prion. Early involvement of hospice and palliative care teams is crucial to optimize patient comfort and quality of life in the advanced stages of this devastating illness.

Access free multiple choice questions on this topic.

References

1.Nafe R, Arendt CT, Hattingen E. Human prion diseases and the prion protein – what is the current state of knowledge? Transl Neurosci. 2023 Jan 01;14(1):20220315. [PMC free article: PMC10579786] [PubMed: 37854584]

2.Bagyinszky E, Giau VV, Youn YC, An SSA, Kim S. Characterization of mutations in PRNP (prion) gene and their possible roles in neurodegenerative diseases. Neuropsychiatr Dis Treat. 2018;14:2067-2085. [PMC free article: PMC6097508] [PubMed: 30147320]

3.Medori R, Montagna P, Tritschler HJ, LeBlanc A, Cortelli P, Tinuper P, Lugaresi E, Gambetti P. Fatal familial insomnia: a second kindred with mutation of prion protein gene at codon 178. Neurology. 1992 Mar;42(3 Pt 1):669-70. [PubMed: 1347910]

4.Schenkein J, Montagna P. Self management of fatal familial insomnia. Part 1: what is FFI? MedGenMed. 2006 Sep 14;8(3):65. [PMC free article: PMC1781306] [PubMed: 17406188]

5.Montagna P, Cortelli P, Avoni P, Tinuper P, Plazzi G, Gallassi R, Portaluppi F, Julien J, Vital C, Delisle MB, Gambetti P, Lugaresi E. Clinical features of fatal familial insomnia: phenotypic variability in relation to a polymorphism at codon 129 of the prion protein gene. Brain Pathol. 1998 Jul;8(3):515-20. [PMC free article: PMC8098256] [PubMed: 9669701]

6.Zerr I, Schmitz M. Genetic Prion Disease. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. University of Washington, Seattle; Seattle (WA): Mar 27, 2003. [PubMed: 20301407]

7.Chen C, Dong XP. Epidemiological characteristics of human prion diseases. Infect Dis Poverty. 2016 Jun 02;5(1):47. [PMC free article: PMC4890484] [PubMed: 27251305]

8.Zhang J, Chu M, Tian Z, Xie K, Cui Y, Liu L, Meng J, Yan H, Ji YM, Jiang Z, Xia TX, Wang D, Wang X, Zhao Y, Ye H, Li J, Wang L, Wu L. Clinical profile of fatal familial insomnia: phenotypic variation in 129 polymorphisms and geographical regions. J Neurol Neurosurg Psychiatry. 2022 Mar;93(3):291-297. [PMC free article: PMC8862016] [PubMed: 34667102]

9.Tinuper P, Montagna P, Medori R, Cortelli P, Zucconi M, Baruzzi A, Lugaresi E. The thalamus participates in the regulation of the sleep-waking cycle. A clinico-pathological study in fatal familial thalamic degeneration. Electroencephalogr Clin Neurophysiol. 1989 Aug;73(2):117-23. [PubMed: 2473878]

10.Montagna P. Fatal familial insomnia and the role of the thalamus in sleep regulation. Handb Clin Neurol. 2011;99:981-96. [PubMed: 21056239]

11.Almer G, Hainfellner JA, Brücke T, Jellinger K, Kleinert R, Bayer G, Windl O, Kretzschmar HA, Hill A, Sidle K, Collinge J, Budka H. Fatal familial insomnia: a new Austrian family. Brain. 1999 Jan;122 ( Pt 1):5-16. [PubMed: 10050890]

12.Krasnianski A, Bartl M, Sanchez Juan PJ, Heinemann U, Meissner B, Varges D, Schulze-Sturm U, Kretzschmar HA, Schulz-Schaeffer WJ, Zerr I. Fatal familial insomnia: Clinical features and early identification. Ann Neurol. 2008 May;63(5):658-61. [PubMed: 18360821]

13.Plazzi G, Schutz Y, Cortelli P, Provini F, Avoni P, Heikkila E, Tinuper P, Solieri L, Lugaresi E, Montagna P. Motor overactivity and loss of motor circadian rhythm in fatal familial insomnia: an actigraphic study. Sleep. 1997 Sep;20(9):739-42. [PubMed: 9406326]

14.Lugaresi E, Medori R, Montagna P, Baruzzi A, Cortelli P, Lugaresi A, Tinuper P, Zucconi M, Gambetti P. Fatal familial insomnia and dysautonomia with selective degeneration of thalamic nuclei. N Engl J Med. 1986 Oct 16;315(16):997-1003. [PubMed: 3762620]

15.Baldelli L, Provini F. Fatal familial insomnia and Agrypnia Excitata: Autonomic dysfunctions and pathophysiological implications. Auton Neurosci. 2019 May;218:68-86. [PubMed: 30890351]

16.Gallassi R, Morreale A, Montagna P, Gambetti P, Lugaresi E. “Fatal familial insomnia”: neuropsychological study of a disease with thalamic degeneration. Cortex. 1992 Jun;28(2):175-87. [PubMed: 1499304]

17.Cortelli P, Fabbri M, Calandra-Buonaura G, Capellari S, Tinuper P, Parchi P, Lugaresi E. Gait disorders in fatal familial insomnia. Mov Disord. 2014 Mar;29(3):420-4. [PubMed: 24375448]

18.Gallassi R, Morreale A, Montagna P, Cortelli P, Avoni P, Castellani R, Gambetti P, Lugaresi E. Fatal familial insomnia: behavioral and cognitive features. Neurology. 1996 Apr;46(4):935-9. [PubMed: 8780067]

19.Montagna P, Cortelli P, Gambetti P, Lugaresi E. Fatal familial insomnia: sleep, neuroendocrine and vegetative alterations. Adv Neuroimmunol. 1995;5(1):13-21. [PubMed: 7795890]

20.Chu M, Xie K, Zhang J, Chen Z, Ghorayeb I, Rupprecht S, Reder AT, Garay A, Honda H, Nagayama M, Shi Q, Zhan S, Nan H, Zhang J, Guan H, Cui L, Guo Y, Rosa-Neto P, Gauthier S, Wang J, Dong X, Wu L. Proposal of new diagnostic criteria for fatal familial insomnia. J Neurol. 2022 Sep;269(9):4909-4919. [PMC free article: PMC9363306] [PubMed: 35501502]

21.Cortelli P, Perani D, Montagna P, Gallassi R, Tinuper P, Provini F, Avoni P, Ferrillo F, Anchisi D, Moresco RM, Fazio F, Parchi P, Baruzzi A, Lugaresi E, Gambetti P. Pre-symptomatic diagnosis in fatal familial insomnia: serial neurophysiological and 18FDG-PET studies. Brain. 2006 Mar;129(Pt 3):668-75. [PubMed: 16399807]

22.Reder AT, Mednick AS, Brown P, Spire JP, Van Cauter E, Wollmann RL, Cervenàkovà L, Goldfarb LG, Garay A, Ovsiew F. Clinical and genetic studies of fatal familial insomnia. Neurology. 1995 Jun;45(6):1068-75. [PubMed: 7783865]

23.Zerr I. Therapeutic trials in human transmissible spongiform encephalo-pathies: recent advances and problems to address. Infect Disord Drug Targets. 2009 Feb;9(1):92-9. [PubMed: 19200019]

24.Forloni G, Tettamanti M, Lucca U, Albanese Y, Quaglio E, Chiesa R, Erbetta A, Villani F, Redaelli V, Tagliavini F, Artuso V, Roiter I. Preventive study in subjects at risk of fatal familial insomnia: Innovative approach to rare diseases. Prion. 2015;9(2):75-9. [PMC free article: PMC4601344] [PubMed: 25996399]

25.Burchell JT, Panegyres PK. Prion diseases: immunotargets and therapy. Immunotargets Ther. 2016;5:57-68. [PMC free article: PMC4970640] [PubMed: 27529062]

26.Medori R, Tritschler HJ, LeBlanc A, Villare F, Manetto V, Chen HY, Xue R, Leal S, Montagna P, Cortelli P. Fatal familial insomnia, a prion disease with a mutation at codon 178 of the prion protein gene. N Engl J Med. 1992 Feb 13;326(7):444-9. [PMC free article: PMC6151859] [PubMed: 1346338]

27.Zerr I, Kallenberg K, Summers DM, Romero C, Taratuto A, Heinemann U, Breithaupt M, Varges D, Meissner B, Ladogana A, Schuur M, Haik S, Collins SJ, Jansen GH, Stokin GB, Pimentel J, Hewer E, Collie D, Smith P, Roberts H, Brandel JP, van Duijn C, Pocchiari M, Begue C, Cras P, Will RG, Sanchez-Juan P. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain. 2009 Oct;132(Pt 10):2659-68. [PMC free article: PMC2759336] [PubMed: 19773352]

28.Cracco L, Appleby BS, Gambetti P. Fatal familial insomnia and sporadic fatal insomnia. Handb Clin Neurol. 2018;153:271-299. [PubMed: 29887141]

29.Hainfellner JA, Brantner-Inthaler S, Cervenáková L, Brown P, Kitamoto T, Tateishi J, Diringer H, Liberski PP, Regele H, Feucht M. The original Gerstmann-Sträussler-Scheinker family of Austria: divergent clinicopathological phenotypes but constant PrP genotype. Brain Pathol. 1995 Jul;5(3):201-11. [PubMed: 8520719]

30.Yang TW, Park B, Kim KT, Jun JS, Kim YS, Lee ST, Jung KH, Chu K, Lee SK, Jung KY. Fatal familial insomnia presenting with agrypnia excitata and very low atonia index level: A case report and literature review. Medicine (Baltimore). 2018 May;97(18):e0646. [PMC free article: PMC6392909] [PubMed: 29718878]

31.Gaudino S, Gangemi E, Colantonio R, Botto A, Ruberto E, Calandrelli R, Martucci M, Vita MG, Masullo C, Cerase A, Colosimo C. Neuroradiology of human prion diseases, diagnosis and differential diagnosis. Radiol Med. 2017 May;122(5):369-385. [PubMed: 28110369]

32.Manix M, Kalakoti P, Henry M, Thakur J, Menger R, Guthikonda B, Nanda A. Creutzfeldt-Jakob disease: updated diagnostic criteria, treatment algorithm, and the utility of brain biopsy. Neurosurg Focus. 2015 Nov;39(5):E2. [PubMed: 26646926]

33.Lindsley CW. Genetic and Rare Disease of the CNS. Part I: Fatal Familial Insomnia (FFI). ACS Chem Neurosci. 2017 Dec 20;8(12):2570-2572. [PubMed: 29258312]

34.Parchi P, Petersen RB, Chen SG, Autilio-Gambetti L, Capellari S, Monari L, Cortelli P, Montagna P, Lugaresi E, Gambetti P. Molecular pathology of fatal familial insomnia. Brain Pathol. 1998 Jul;8(3):539-48. [PMC free article: PMC8098344] [PubMed: 9669705]

35.Montagna P, Gambetti P, Cortelli P, Lugaresi E. Familial and sporadic fatal insomnia. Lancet Neurol. 2003 Mar;2(3):167-76. [PubMed: 12849238]